1. Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

3. Case #1

4. Monitoring Post-ASCT Blood Testing

5. Other Monitoring After Initial Therapy

6. Case #1 (cont)

7. Assessment at Relapse Symptomatic First Relapse

8. Cytogenetic Testing at Relapse

9. Therapy Selection Considerations

10. Recent Phase 3 Trials in R/R MM

11. ASPIRE Len/Dex ± Carfilzomib

12. TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

13. ELOQUENT-2 Len/Dex ± Elotuzumab

14. POLLUX Len/Dex ± Daratumumab

15. CASTOR Bor/Dex ± Daratumumab

16. ENDEAVOR Carfilzomib/Dex vs Bor/Dex

17. PANORAMA-1 Panobinostat/Bor/Dex vs Placebo/Bor/Dex

18. Recent Phase 3 Trials in R/R MM

19. Other Issues to Consider

20. Special Safety Considerations

21. Role of Second ASCT in First Relapse

22. Select Emerging Agents in MM

23. Key Takeaways

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)